ECIA logo

Encision Inc. (ECIA)

For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Encision Inc. (ECIA) with AI Score 43/100 (Weak). Encision Inc. specializes in designing, developing, and manufacturing surgical instruments with a focus on patient safety through its Active Electrode Monitoring (AEM) technology. Market cap: 0, Sector: Healthcare.

Last analyzed: Mar 17, 2026
Encision Inc. specializes in designing, developing, and manufacturing surgical instruments with a focus on patient safety through its Active Electrode Monitoring (AEM) technology. The company's products are sold through a network of direct and independent sales representatives within the United States.
43/100 AI Score

Encision Inc. (ECIA) Healthcare & Pipeline Overview

CEORobert H. Fries
Employees22
HeadquartersBoulder, US
IPO Year2004

Encision Inc. is a medical device company focused on enhancing patient safety in laparoscopic surgical procedures through its patented Active Electrode Monitoring (AEM) technology. The company designs, manufactures, and markets AEM surgical instruments and monitors, primarily within the United States, utilizing a direct and independent sales network.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: Mar 17, 2026

Investment Thesis

Encision Inc. presents a focused investment opportunity within the niche market of surgical safety. The company's patented AEM technology offers a potential competitive advantage by addressing the risk of stray energy burns during laparoscopic procedures. With a gross margin of 52.6%, there is potential for profitability if sales can be scaled effectively. Key growth catalysts include expanding the adoption of AEM technology in hospitals and surgical centers and introducing new AEM-integrated instruments. However, the company's small market capitalization and negative profit margin (-6.0%) indicate significant financial risks. The company's ability to increase sales and manage costs effectively will be crucial for long-term success. Monitoring the company's progress in securing new contracts and expanding its sales network will be essential for evaluating its growth potential.

Based on FMP financials and quantitative analysis

Key Highlights

  • Encision Inc. operates in the medical device industry, specifically focusing on surgical instruments and supplies.
  • The company's Active Electrode Monitoring (AEM) technology aims to enhance patient safety during laparoscopic procedures.
  • Encision's product line includes AEM-integrated endo-mechanical instruments, handles, and the EndoShield 2 burn protection system.
  • The company distributes its products through a network of direct and independent sales representatives in the United States.
  • Encision's gross margin stands at 52.6%, indicating potential for profitability with increased sales volume.

Competitors & Peers

Strengths

  • Patented AEM technology for enhanced patient safety.
  • Specialized product line focused on laparoscopic surgery.
  • Direct and independent sales representative network.
  • Gross margin of 52.6%.

Weaknesses

  • Small market capitalization.
  • Negative profit margin (-6.0%).
  • Limited geographic reach (primarily United States).
  • Dependence on a niche market.

Catalysts

  • Upcoming: Potential FDA approval for new AEM-integrated surgical instruments.
  • Ongoing: Expansion of the sales network into new geographic regions.
  • Ongoing: Increased adoption of AEM technology in hospitals and surgical centers.
  • Upcoming: Publication of clinical studies validating the effectiveness of AEM technology.

Risks

  • Potential: Competition from larger medical device companies with greater resources.
  • Ongoing: Limited financial resources and negative profit margin.
  • Potential: Regulatory changes affecting medical devices.
  • Ongoing: Dependence on a niche market.
  • Potential: Product liability claims related to surgical instruments.

Growth Opportunities

  • Expansion into new therapeutic areas: Encision can explore expanding the application of its AEM technology into other surgical specialties beyond general laparoscopy. This could include areas such as gynecological surgery, urological surgery, and bariatric surgery. Each of these areas represents a significant market opportunity, potentially increasing Encision's addressable market by millions of dollars. The timeline for this expansion would involve conducting clinical studies to validate the effectiveness of AEM in these new areas, followed by regulatory approvals and targeted marketing campaigns.
  • Geographic expansion beyond the United States: Currently, Encision primarily sells its products within the United States. Expanding into international markets, particularly Europe and Asia, represents a significant growth opportunity. These markets have a growing demand for advanced surgical instruments and a strong emphasis on patient safety. The timeline for international expansion would involve obtaining regulatory approvals in each target market, establishing distribution partnerships, and adapting its products to meet local market needs. This expansion could potentially double Encision's revenue within 3-5 years.
  • Development of new AEM-integrated instruments: Encision can invest in the development of new surgical instruments that incorporate its AEM technology. This could include specialized instruments for specific surgical procedures or advanced instruments with enhanced features and functionality. The market for innovative surgical instruments is constantly evolving, and Encision can capitalize on this trend by introducing new products that address unmet needs. The timeline for new product development would involve conducting market research, designing and prototyping new instruments, and obtaining regulatory approvals.
  • Strategic partnerships with hospitals and surgical centers: Encision can establish strategic partnerships with leading hospitals and surgical centers to promote the adoption of its AEM technology. These partnerships could involve providing training and support to surgeons, conducting joint research studies, and offering customized solutions to meet the specific needs of each institution. By building strong relationships with key stakeholders, Encision can increase its market share and establish itself as a trusted provider of surgical safety solutions. The timeline for establishing these partnerships would involve identifying key institutions, developing customized proposals, and negotiating partnership agreements.
  • Increased focus on marketing and sales efforts: Encision can invest in strengthening its marketing and sales efforts to increase awareness of its AEM technology and drive sales growth. This could include expanding its sales team, attending industry conferences and trade shows, and launching targeted marketing campaigns. By effectively communicating the benefits of AEM technology to surgeons and hospital administrators, Encision can increase its market penetration and accelerate its growth trajectory. The timeline for implementing these marketing and sales initiatives would involve developing a comprehensive marketing plan, allocating resources to key activities, and tracking the results of each campaign.

Opportunities

  • Expansion into new therapeutic areas.
  • Geographic expansion into international markets.
  • Development of new AEM-integrated instruments.
  • Strategic partnerships with hospitals and surgical centers.

Threats

  • Competition from larger medical device companies.
  • Technological advancements by competitors.
  • Regulatory changes affecting medical devices.
  • Economic downturn impacting hospital budgets.

Competitive Advantages

  • Patented Active Electrode Monitoring (AEM) technology.
  • Focus on patient safety in laparoscopic procedures.
  • Specialized product line of AEM-integrated surgical instruments.

About ECIA

Encision Inc., established in 1991 and based in Boulder, Colorado, is a medical device company dedicated to improving patient safety during laparoscopic surgical procedures. The company designs, develops, manufactures, and markets patented surgical instruments featuring Active Electrode Monitoring (AEM) technology. This technology is designed to minimize the risk of stray energy burns during surgery, a significant concern in laparoscopic procedures. Encision's core product line includes a range of endo-mechanical instruments such as scissors, graspers, and dissectors, all integrated with AEM. They also offer fixed-tip electrodes and suction-irrigation electrodes. These instruments are complemented by various handles designed for advanced laparoscopic procedures, incorporating stiffer shafts and ergonomic features for surgeons. Furthermore, Encision markets the AEM EndoShield 2 burn protection system and AEM monitors, which are used in conjunction with their AEM instruments to provide real-time monitoring and enhanced safety. The company distributes its products through a network of direct and independent sales representatives, primarily targeting hospitals and surgical centers within the United States. Encision's focus on AEM technology differentiates it from competitors, emphasizing safety and patient outcomes in the minimally invasive surgery market.

What They Do

  • Designs and develops surgical instruments.
  • Manufactures patented surgical instruments.
  • Markets surgical instruments in the United States.
  • Provides Active Electrode Monitoring (AEM) surgical instruments.
  • Offers AEM monitors for enhanced patient safety.
  • Sells through direct and independent sales representatives.

Business Model

  • Designs, develops, and manufactures AEM surgical instruments.
  • Sells AEM instruments and monitors to hospitals and surgical centers.
  • Distributes products through a network of direct and independent sales representatives.

Industry Context

Encision Inc. operates within the medical instruments and supplies industry, a segment of the broader healthcare sector. This industry is characterized by technological innovation, stringent regulatory requirements, and a focus on improving patient outcomes. The market for laparoscopic surgical instruments is growing, driven by the increasing adoption of minimally invasive procedures. Key trends include the development of more sophisticated surgical tools, the integration of advanced technologies such as robotics and imaging, and a growing emphasis on patient safety. Encision's focus on AEM technology positions it within the patient safety segment of this market, competing with larger medical device companies and smaller specialized firms.

Key Customers

  • Hospitals
  • Surgical centers
  • Surgeons
AI Confidence: 71% Updated: Mar 17, 2026

Financials

Chart & Info

Encision Inc. (ECIA) stock price: Price data unavailable

Latest News

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ECIA.

Price Targets

Wall Street price target analysis for ECIA.

MoonshotScore

43/100

What does this score mean?

The MoonshotScore rates ECIA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Leadership: Robert H. Fries

CEO

Robert H. Fries serves as the CEO of Encision Inc. His background includes extensive experience in managing and leading teams within the medical device industry. He is responsible for overseeing the company's strategic direction, product development, and sales and marketing efforts. His leadership is focused on driving growth and innovation within the organization.

Track Record: Under Robert H. Fries' leadership, Encision Inc. has focused on expanding its product line and strengthening its sales network. Key milestones include the development and launch of new AEM-integrated instruments and the expansion of the company's distribution partnerships. He manages a team of 22 employees.

ECIA OTC Market Information

The OTC Other tier represents the lowest tier of the OTC market, indicating that Encision Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited information and increased volatility.

  • OTC Tier: OTC Other
  • Disclosure Status: Unknown
Liquidity: Liquidity for stocks on the OTC Other tier is typically very limited. Trading volume is often low, and bid-ask spreads can be wide, making it difficult to buy or sell shares at desired prices. This lack of liquidity can increase the risk of significant price fluctuations and make it challenging to exit a position quickly. Investors should be prepared for potential delays and price slippage when trading ECIA.
OTC Risk Factors:
  • Limited financial disclosure.
  • Low trading volume and liquidity.
  • Potential for price manipulation.
  • Higher risk of fraud or mismanagement.
  • Limited regulatory oversight.
Due Diligence Checklist:
  • Verify the company's management team and their track record.
  • Review the company's financial statements, if available.
  • Assess the company's business model and competitive landscape.
  • Check for any legal or regulatory issues.
  • Monitor trading volume and price activity.
  • Understand the risks associated with investing in OTC stocks.
  • Consult with a financial advisor.
Legitimacy Signals:
  • Company has been in business since 1991.
  • Focus on patented AEM technology.
  • Distribution through direct and independent sales representatives.
  • Operates in the regulated medical device industry.

ECIA Healthcare Stock FAQ

What does Encision Inc. do?

Encision Inc. is a medical device company specializing in the design, development, manufacturing, and marketing of surgical instruments. Its core focus is on enhancing patient safety during laparoscopic surgical procedures through its patented Active Electrode Monitoring (AEM) technology. This technology aims to minimize the risk of stray energy burns, a common concern in laparoscopic surgery. The company offers a range of AEM-integrated instruments, including scissors, graspers, dissectors, and monitors, which are sold through a network of direct and independent sales representatives primarily within the United States.

What do analysts say about ECIA stock?

As of 2026-03-17, there is no readily available analyst coverage or consensus for Encision Inc. (ECIA). Given the company's small market capitalization and OTC listing, it is less likely to be actively followed by major research firms. Investors should conduct their own due diligence and consider the company's financial performance, growth prospects, and risk factors before making any investment decisions. Key metrics to monitor include revenue growth, gross margin, and progress in expanding the adoption of AEM technology.

What are the main risks for ECIA?

Encision Inc. faces several risks, including competition from larger medical device companies with greater resources, limited financial resources and a negative profit margin, regulatory changes affecting medical devices, dependence on a niche market, and potential product liability claims related to surgical instruments. As an OTC-listed company, ECIA also faces risks associated with limited liquidity, disclosure, and regulatory oversight. Investors should carefully consider these risks before investing in ECIA.

What are the key factors to evaluate for ECIA?

Encision Inc. (ECIA) currently holds an AI score of 43/100, indicating low score. Key strength: Patented AEM technology for enhanced patient safety.. Primary risk to monitor: Potential: Competition from larger medical device companies with greater resources.. This is not financial advice.

How frequently does ECIA data refresh on this page?

ECIA prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven ECIA's recent stock price performance?

Recent price movement in Encision Inc. (ECIA) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Patented AEM technology for enhanced patient safety.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider ECIA overvalued or undervalued right now?

Determining whether Encision Inc. (ECIA) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying ECIA?

Before investing in Encision Inc. (ECIA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .

Data provided for informational purposes only.

Analysis Notes
  • Limited analyst coverage for ECIA.
  • OTC market carries higher risks.
Data Sources

Popular Stocks